These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 33493500)

  • 21. The effect of catheter displacement and anatomical variations on the dose distribution in MRI-guided focal HDR brachytherapy for prostate cancer.
    Maenhout M; van der Voort van Zyp JRN; Borot de Battisti M; Peters M; van Vulpen M; van den Bosch M; Moerland MA
    Brachytherapy; 2018; 17(1):68-77. PubMed ID: 28579419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
    Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
    Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome.
    Jiang P; van der Horst C; Kimmig B; Zinsser F; Poppe B; Luetzen U; Juenemann KP; Dunst J; Siebert FA
    Brachytherapy; 2017; 16(1):186-192. PubMed ID: 28341011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial.
    Alayed Y; D'Alimonte L; Helou J; Ravi A; Morton G; Chung HT; Haider M; McGuffin M; Zhang L; Loblaw A
    Radiother Oncol; 2019 Dec; 141():144-148. PubMed ID: 31564554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dosimetric evaluation of MRI-to-ultrasound automated image registration algorithms for prostate brachytherapy.
    Shaaer A; Paudel M; Davidson M; Semple M; Nicolae A; Mendez LC; Chung H; Loblaw A; Tseng CL; Morton G; Ravi A
    Brachytherapy; 2020; 19(5):599-606. PubMed ID: 32712028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy.
    Hermesse J; Biver S; Jansen N; Lenaerts E; De Patoul N; Vynckier S; Coucke P; Scalliet P; Nickers P
    Strahlenther Onkol; 2009 Nov; 185(11):736-42. PubMed ID: 19899007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy.
    Tsang YM; Tharmalingam H; Belessiotis-Richards K; Armstrong S; Ostler P; Hughes R; Alonzi R; Hoskin PJ
    Radiother Oncol; 2021 May; 158():184-190. PubMed ID: 33639192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion.
    Crook J; Ots A; Gaztañaga M; Schmid M; Araujo C; Hilts M; Batchelar D; Parker B; Bachand F; Milette MP
    Brachytherapy; 2014; 13(5):433-41. PubMed ID: 24958556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 15-year outcomes of high-dose-rate brachytherapy for radical dose escalation in patients with prostate cancer - a benchmark for high-tech external beam radiotherapy alone?
    Galalae RM; Zakikhany NH; Geiger F; Siebert FA; Bockelmann G; Schultze J; Kimmig B
    Brachytherapy; 2014; 13(2):117-22. PubMed ID: 24360880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer.
    Siddiqui ZA; Gustafson GS; Ye H; Martinez AA; Mitchell B; Sebastian E; Limbacher A; Krauss DJ
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1038-1044. PubMed ID: 30771408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy - preliminary results.
    Jo Y; Fujii T; Hara R; Yokoyama T; Miyaji Y; Yoden E; Hiratsuka J; Nagai A
    BJU Int; 2012 Mar; 109(6):835-9. PubMed ID: 21933327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.
    Fukuda S; Seo Y; Shiomi H; Yamada Y; Ogata T; Morimoto M; Konishi K; Yoshioka Y; Ogawa K
    J Radiat Res; 2014 Nov; 55(6):1114-21. PubMed ID: 24957754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.
    Morton G; McGuffin M; Chung HT; Tseng CL; Helou J; Ravi A; Cheung P; Szumacher E; Liu S; Chu W; Zhang L; Mamedov A; Loblaw A
    Radiother Oncol; 2020 May; 146():90-96. PubMed ID: 32146259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept.
    Fokdal L; Tanderup K; Nielsen SK; Christensen HK; Røhl L; Pedersen EM; Schønemann NK; Lindegaard JC
    Radiother Oncol; 2011 Sep; 100(3):473-9. PubMed ID: 21924784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life.
    Sanmamed N; Lee J; Berlin A; Craig T; Lao B; Rink A; Bayley A; Catton C; Sundaramurthy A; Foltz W; McPartlin A; Ghai S; Astenafu E; Gospodarowicz M; Warde P; Ménard C; Chung P
    Radiother Oncol; 2020 Aug; 149():240-245. PubMed ID: 32447033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life.
    Maenhout M; Peters M; Moerland MA; Meijer RP; van den Bosch MAAJ; Frank SJ; Nguyen PL; van Vulpen M; van der Voort van Zyp JRN
    Radiother Oncol; 2018 Dec; 129(3):554-560. PubMed ID: 30131183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
    Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
    Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI-Guided Ultrafocal Salvage High-Dose-Rate Brachytherapy for Localized Radiorecurrent Prostate Cancer: Updated Results of 50 Patients.
    van Son MJ; Peters M; Moerland MA; Lagendijk JJW; Eppinga WSC; Shah TT; Ahmed HU; van der Voort van Zyp JRN
    Int J Radiat Oncol Biol Phys; 2020 May; 107(1):126-135. PubMed ID: 32006609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of prostate volume on outcome after high-dose-rate brachytherapy alone for localized prostate cancer.
    Le H; Rojas A; Alonzi R; Hughes R; Ostler P; Lowe G; Bryant L; Hoskin P
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):270-4. PubMed ID: 23849693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.